2022 年第 1 期 第 17 卷

芪苈强心胶囊联合重组人脑利钠肽治疗对急性左心衰竭患者心功能的影响

Effect of Qiliqiangxin capsule combined with recombinant human brain natriuretic peptide on cardiac function in patients with acute left heart failure

作者：叶明1王鑫2孙悦2黄觊1高海1

英文作者：Ye Ming1 Wang Xin2 Sun Yue2 Huang Ji1 Gao Hai1

单位：1首都医科大学附属北京安贞医院急诊危重症中心，北京100029；2吉林省人民医院心内科，长春130021

英文单位：1Department of Emergency and Critical Care Center Beijing Anzhen Hospital Capital Medical University Beijing 100029 China; 2Department of Cardiology Jilin Province People′s Hospital Changchun 130021 China

关键词：急性左心衰竭；芪苈强心胶囊；重组人脑利钠肽

英文关键词：Acuteleftheartfailure;Qiliqiangxincapsule;Recombinanthumanbrainnatriureticpeptide

• 摘要：

• 目的 观察芪苈强心胶囊联合重组人脑利钠肽治疗对急性左心衰竭患者心功能的影响。方法 选取首都医科大学附属北京安贞医院急诊危重症中心与吉林省人民医院心内科2017年10月至2021年5月因急性左心衰竭入院患者240例，按照随机数字表法分为常规治疗组和联合治疗组，各120例。常规治疗组予以扩血管、利尿、强心、重组人脑利钠肽等治疗。联合治疗组在常规治疗组的基础上予以芪苈强心胶囊口服治疗。治疗7 d后，比较2组患者左心室射血分数（LVEF）、左心室舒张末期内径（LVEDD）以及血浆B型脑钠肽（BNP）、半乳糖凝集素3（Gal-3）、胱抑素C、可溶性生长刺激表达基因2蛋白(sST2)水平变化。结果 治疗7 d后，2组LVEDD明显低于治疗前且联合治疗组明显低于常规治疗组［（52±5）mm比（56±6）mm］，LVEF明显高于治疗前且联合治疗组明显高于常规治疗组［（52±7）%比（46±7）%］，差异均有统计学意义（均P＜0.05）。治疗7 d后，2组患者血浆BNP、Gal-3、胱抑素C及sST2水平均低于治疗前，且联合治疗组明显低于常规治疗组［（1 032±371）mmol/L比（1 561±352）mmol/L、（5.8±1.3）μg/L比（8.3±1.7）μg/L、（0.71±0.14）ng/L比（1.08±0.12）ng/L、（152±37）mg/L比（180±40）mg/L］，差异均有统计学意义（均P＜0.05）。结论  芪苈强心胶囊联合重组人脑利钠肽治疗能有效改善急性左心衰竭患者心功能，降低血浆BNP、Gal-3、胱抑素C和sST2水平。

• Objective   To observe the effect of Qiliqiangxin capsule combined with recombinant human brain natriuretic peptide on cardiac function in patients with acute left heart failure. Methods  From October 2017 to May 2021, 240 inpatients with acute left heart failure were selected from Department of Emergency and Critical Care Center, Beijing Anzhen Hospital, Capital Medical University and Department of Cardiology, Jilin Province People′s Hospital. They were randomly divided into routine treatment group and combined treatment group, with 120 cases in each group. The routine treatment group was treated with vasodilation, diuresis, cardiotonic and recombinant human brain natriuretic peptide. The combined treatment group was treated with Qiliqiangxin capsule on the basis of routine treatment group. After 7 d of treatment, the changes of left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVEDD), plasma brain natriuretic peptide (BNP), galectin-3 (Gal-3), Cystatin C (CysC) and soluble growth stimulating gene 2 protein (sST2) were compared between the two groups. Results  After 7 d of treatment, LVEDD in the two groups were significantly lower than those before treatment, and that in the combined treatment group was significantly lower than that in the conventional treatment group ［(52±5)mm vs (56±6)mm］; LVEF in the two groups were significantly higher than those before treatment, and that in the combined treatment group was significantly higher than that in the conventional treatment group ［(52±7)% vs (46±7)%］(all P＜0.05). After 7 d of treatment, the levels of plasma BNP, Gal-3, CysC and sST2 in the two groups were lower than those before treatment, and those in the combined treatment group were significantly lower than those in the conventional treatment group［（1 032±371）mmol/L vs （1 561±352）mmol/L, （5.8±1.3）μg/L vs （8.3±1.7）μg/L, （0.71±0.14）ng/L vs （1.08±0.12）ng/L, （152±37）mg/L vs （180±40）mg/L］(all P＜0.05). Conclusion  Qiliqiangxin capsule combined with recombinant human brain natriuretic peptide can effectively improve cardiac function, and reduce the levels of plasma BNP, Gal-3, CysC and sST2 in patients with acute left heart failure.